Copyright
ELSEVIER (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - March 25, 2022 Category: Cardiology Source Type: research
Contributors
EDUARDO BOSSONE, MD, PhD, FCCP, FESC, FACC (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - March 25, 2022 Category: Cardiology Source Type: research
Contents
Dipti Itchhaporia, Ragavendra R. Baliga and Eduardo Bossone (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - March 25, 2022 Category: Cardiology Source Type: research
Forthcoming Issues
Translational Research in Cardio-Oncology (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - March 25, 2022 Category: Cardiology Source Type: research
Using Artificial Intelligence to Better Predict and Develop Biomarkers
Advancements in technology have improved biomarker discovery in the field of heart failure (HF). What was once a slow and laborious process has gained efficiency through use of high-throughput omics platforms to phenotype HF at the level of genes, transcripts, proteins, and metabolites. Furthermore, improvements in artificial intelligence (AI) have made the interpretation of large omics data sets easier and improved analysis. Use of omics and AI in biomarker discovery can aid clinicians by identifying markers of risk for developing HF, monitoring care, determining prognosis, and developing druggable targets. Combined, AI h...
Source: Heart Failure Clinics - March 8, 2022 Category: Cardiology Authors: Sam A. Michelhaugh, James L. Januzzi Source Type: research
Digital Transformation in Medicine to Enhance Quality of Life, Longevity, and Health Equity
Cardiovascular medicine is inherently a "high-tech" profession, with a long history of adopting new technologies to help improve patient outcomes (Fig. 1). However, health care delivery to improve efficiency and to optimize health outcomes has not advanced. And while many major sectors of the economy, including finance, transportation, and entertainment, have embraced digital transformation with improved performance metrics, health care has been slower to embrace it. (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - March 8, 2022 Category: Cardiology Authors: Ragavendra R. Baliga, Dipti Itchhaporia, Eduardo Bossone Tags: Preface Source Type: research
Rare Cardiovascular Diseases: From Genetics to Personalized Medicine
Rare cardiovascular diseases represent a significant public health problem worldwide and, despite their low prevalence, have major effects on the quality of life of the affected patients and their families. (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - November 12, 2021 Category: Cardiology Authors: Giuseppe Limongelli, Emanuele Monda, Michele Lioncino, Eduardo Bossone Tags: Preface Source Type: research
Rare Cardiovascular Diseases
HEART FAILURE CLINICS (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - November 12, 2021 Category: Cardiology Authors: Giuseppe Limongelli, Emanuele Monda, Michele Lioncino, Eduardo Bossone Source Type: research
Copyright
ELSEVIER (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - November 12, 2021 Category: Cardiology Source Type: research
Contributors
EDUARDO BOSSONE, MD, PhD, FCCP, FESC, FACC (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - November 12, 2021 Category: Cardiology Source Type: research
Contents
Giuseppe Limongelli, Emanuele Monda, Michele Lioncino and Eduardo Bossone (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - November 12, 2021 Category: Cardiology Source Type: research
Forthcoming Issues
Digital Health (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - November 12, 2021 Category: Cardiology Source Type: research
Cardiovascular Involvement in mtDNA Disease
Mitochondrial diseases (MD) include an heterogenous group of systemic disorders caused by sporadic or inherited mutations in nuclear or mitochondrial DNA (mtDNA), causing impairment of oxidative phosphorylation system. Hypertrophic cardiomyopathy is the dominant pattern of cardiomyopathy in all forms of mtDNA disease, being observed in almost 40% of the patients. Dilated cardiomyopathy, left ventricular noncompaction, and conduction system disturbances have been also reported. In this article, the authors discuss the current clinical knowledge on MD, focusing on diagnosis and management of mitochondrial diseases caused by ...
Source: Heart Failure Clinics - October 26, 2021 Category: Cardiology Authors: Michele Lioncino, Emanuele Monda, Martina Caiazza, Adelaide Fusco, Annapaolo Cirillo, Francesca Dongiglio, Vicenzo Simonelli, Simone Sampaolo, Lucia Ruggiero, Gioacchino Scarano, Vicenzo Pota, Giulia Frisso, Cristina Mazzaccara, Giulia D'Amati, Gerardo Ni Source Type: research
Genetics in Congenital Heart Diseases
The genetic background of congenital heart diseases (CHDs) is extremely complex, heterogenous, and still majorly to be determined. CHDs can be sporadic or familial. In this article we discuss in detail the phenotypic spectrum of selected genes including MYH7, GATA4, NKX2-5, TBX5, and TBX20. Our goal is to offer the clinician a general overview of the clinical spectrum of the analyzed topics that are traditionally known as causative for CHDs but we underline in this review the possible progressive functional (cardiomyopathy) and electric aspects (arrhythmias) caused by the genetic background. (Source: Heart Failure Clinics)
Source: Heart Failure Clinics - October 26, 2021 Category: Cardiology Authors: Anwar Baban, Valentina Lodato, Giovanni Parlapiano, Fabrizio Drago Source Type: research
Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a homozygous GAA triplet repeat expansion in the frataxin gene. Cardiac involvement, usually manifesting as hypertrophic cardiomyopathy, can range from asymptomatic cases to severe cardiomyopathy with progressive deterioration of the left ventricular ejection fraction and chronic heart failure. The management of cardiac involvement is directed to prevent disease progression and cardiovascular complications. However, direct-disease therapies are not currently available for FRDA. The present review aims to describe the current state of kn...
Source: Heart Failure Clinics - October 25, 2021 Category: Cardiology Authors: Emanuele Monda, Michele Lioncino, Marta Rubino, Silvia Passantino, Federica Verrillo, Martina Caiazza, Annapaola Cirillo, Adelaide Fusco, Francesco Di Fraia, Fabio Fimiani, Federica Amodio, Nunzia Borrelli, Alfredo Mauriello, Francesco Natale, Gioacchino Source Type: research
